GW572016 For Treatment Of Refractory Metastatic Breast Cancer
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
This study was designed to determine the efficacy of an oral dual kinase inhibitor for the treatment of metastatic breast cancer tumors that are known to overexpress ErbB2 in a refractory patient population.
An Open-Label, Multicenter, Single Arm Phase II Study of Oral GW572016 as Single Agent Therapy in Subjects With Advanced or Metastatic Breast Cancer Who Have Progressed While Receiving HERCEPTIN-Containing Regimens
Study Start Date
Primary Completion Date
Study Completion Date
Resource links provided by the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Signed Informed Consent.
Histologically confirmed Stage IIIb or IV breast cancer.
Refractory breast cancer defined as progression in the metastatic setting after prior therapy with anthracyclines, taxanes and capecitibine.
Subjects with documented ErbB2 tumor overexpression must have received at least 6 cycles of trastuzumab.
Documented disease progression of the most recent treatment is required.
Archived tumor tissue available for testing.
Measurable lesions according to Response Evaluation Criteria In Solid Tumors (RECIST).
At least 3 weeks since prior cancer therapies except for trastuzumab which must be discontinued at least 2 weeks prior to the beginning of study drug.
Bisphosphonate therapy initiated prior to study entry is allowed, however, initiation of bisphosphonates following study entry is not allowed.
Able to swallow and retain oral medication.
Cardiac ejection fraction within the institutional normal range as measured by echocardiogram or MUGA (Multiple Gated Acquisition) scan.
Adequate kidney and liver function.
Adequate bone marrow function.
Pregnant or lactating.
Copies of nadir scans and/or photographs of the tumor prior to disease progression as well as scans documenting disease progression are not available for review.
Malabsorption syndrome, ulcerative colitis, disease significantly affecting gastrointestinal function or resection of the stomach or small bowel.
History of other malignancy.
Serious medical or psychiatric disorder that would interfere with the patient''s safety or informed consent.
Active or uncontrolled infection.
Known history of uncontrolled or symptomatic angina, arrhythmias or congestive heart failure.
Known history of or clinical evidence of leptomeningeal carcinomatosis.
Concurrent cancer therapy or investigational therapy.
Use of oral or IV steroids.
Unresolved or unstable serious toxicity from prior therapy.
Prior treatment with an ErbB1 and/or ERbB2 inhibitor other than trastuzumab.